Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

Hepatitis A virus (HAV) infection rarely causes fulminant hepatic failure in people with no underlying chronic liver disease. 1 The outcome of hepatitis A in patients with chronic hepatitis B has been addressed in a few reports. 2 To determine whether the course and the outcome of acute hepatitis A...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The New England journal of medicine 1998-01, Vol.338 (5), p.286-290
Hauptverfasser: Vento, Sandro, Garofano, Tiziana, Renzini, Carlo, Cainelli, Francesca, Casali, Ferruccio, Ghironzi, Giancarlo, Ferraro, Teresa, Concia, Ercole
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Biological and medical sciences
Case-Control Studies
Deoxyribonucleic acid
DNA
DNA, Viral - isolation & purification
Female
Hepatic Encephalopathy - etiology
Hepatitis
Hepatitis A - complications
Hepatitis B, Chronic - complications
Hepatitis C, Chronic - complications
Human viral diseases
Humans
Infectious diseases
Interferon
Liver diseases
Liver Function Tests
Male
Medical sciences
Polymerase chain reaction
Prospective Studies
RNA, Viral - isolation & purification
Superinfection - complications
Viral diseases
Viral hepatitis
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Hepatitis A virus (HAV) infection rarely causes fulminant hepatic failure in people with no underlying chronic liver disease. 1 The outcome of hepatitis A in patients with chronic hepatitis B has been addressed in a few reports. 2 To determine whether the course and the outcome of acute hepatitis A differ between patients with chronic hepatitis C and those with chronic hepatitis B, we prospectively followed, for 86 months, 432 patients with chronic hepatitis C and 163 patients with chronic hepatitis B, testing for serum IgM and IgG antibodies to HAV (anti-HAV) every 4 months. We report the clinical and virologic course . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJM199801293380503